Bootstrap Confidence Intervals for Multilevel Standardized Effect Size

Author(s):  
Mark H. C. Lai
Methodology ◽  
2021 ◽  
Vol 17 (1) ◽  
pp. 1-21
Author(s):  
Johnson Ching-Hong Li ◽  
Virginia Man Chung Tze

Evaluating how an effect-size estimate performs between two continuous variables based on the common-language effect size (CLES) has received increasing attention. While Blomqvist (1950; https://doi.org/10.1214/aoms/1177729754) developed a parametric estimator (q') for the CLES, there has been limited progress in further refining CLES. This study: a) extends Blomqvist’s work by providing a mathematical foundation for Bp (a non-parametric version of CLES) and an analytic approach for estimating its standard error; and b) evaluates the performance of the analytic and bootstrap confidence intervals (CIs) for Bp. The simulation shows that the bootstrap bias-corrected-and-accelerated interval (BCaI) has the best protected Type 1 error rate with a slight compromise in Power, whereas the analytic-t CI has the highest overall Power but with a Type 1 error slightly larger than the nominal value. This study also uses a real-world data-set to demonstrate the applicability of the CLES in measuring the relationship between age and sexual compulsivity.


2019 ◽  
Author(s):  
Amanda Kay Montoya ◽  
Andrew F. Hayes

Researchers interested in testing mediation often use designs where participants are measured on a dependent variable Y and a mediator M in both of two different circumstances. The dominant approach to assessing mediation in such a design, proposed by Judd, Kenny, and McClelland (2001), relies on a series of hypothesis tests about components of the mediation model and is not based on an estimate of or formal inference about the indirect effect. In this paper we recast Judd et al.’s approach in the path-analytic framework that is now commonly used in between-participant mediation analysis. By so doing, it is apparent how to estimate the indirect effect of a within-participant manipulation on some outcome through a mediator as the product of paths of influence. This path analytic approach eliminates the need for discrete hypothesis tests about components of the model to support a claim of mediation, as Judd et al’s method requires, because it relies only on an inference about the product of paths— the indirect effect. We generalize methods of inference for the indirect effect widely used in between-participant designs to this within-participant version of mediation analysis, including bootstrap confidence intervals and Monte Carlo confidence intervals. Using this path analytic approach, we extend the method to models with multiple mediators operating in parallel and serially and discuss the comparison of indirect effects in these more complex models. We offer macros and code for SPSS, SAS, and Mplus that conduct these analyses.


Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
George A Diamond ◽  
Sanjay Kaul

Background A highly publicized meta-analysis of 42 clinical trials comprising 27,844 diabetics ignited a firestorm of controversy by charging that treatment with rosiglitazone was associated with a “…worrisome…” 43% greater risk of myocardial infarction ( p =0.03) and a 64% greater risk of cardiovascular death ( p =0.06). Objective The investigators excluded 4 trials from the infarction analysis and 19 trials from the mortality analysis in which no events were observed. We sought to determine if these exclusions biased the results. Methods We compared the index study to a Bayesian meta-analysis of the entire 42 trials (using odds ratio as the measure of effect size) and to fixed-effects and random-effects analyses with and without a continuity correction that adjusts for values of zero. Results The odds ratios and confidence intervals for the analyses are summarized in the Table . Odds ratios for infarction ranged from 1.43 to 1.22 and for death from 1.64 to 1.13. Corrected models resulted in substantially smaller odds ratios and narrower confidence intervals than did uncorrected models. Although corrected risks remain elevated, none are statistically significant (*p<0.05). Conclusions Given the fragility of the effect sizes and confidence intervals, the charge that roziglitazone increases the risk of adverse events is not supported by these additional analyses. The exaggerated values observed in the index study are likely the result of excluding the zero-event trials from analysis. Continuity adjustments mitigate this error and provide more consistent and reliable assessments of true effect size. Transparent sensitivity analyses should therefore be performed over a realistic range of the operative assumptions to verify the stability of such assessments especially when outcome events are rare. Given the relatively wide confidence intervals, additional data will be required to adjudicate these inconclusive results.


2017 ◽  
Vol 42 (11) ◽  
pp. 4565-4573 ◽  
Author(s):  
Muhammad Kashif ◽  
Muhammad Aslam ◽  
G. Srinivasa Rao ◽  
Ali Hussein AL-Marshadi ◽  
Chi-Hyuck Jun

Sign in / Sign up

Export Citation Format

Share Document